Thyroid Disorders in ITP Patients
Part of Blood & lymphatic, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at whether people with immune thrombocytopenia (ITP) also have thyroid problems and if that affects their treatment. It could help doctors better understand and manage both conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ITP (immune thrombocytopenia) that is newly diagnosed, persistent (3–12 months), or chronic (more than 12 months).
- Your ITP is not responding to treatment (refractory).
- You have not had your thyroid removed (thyroidectomy).
- Your ITP is not caused by a medication.
- You do not have hepatitis C, hepatitis B, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at specific immune blood tests to understand why some people with immune thrombocytopenia (ITP) also develop blood clots. Results may help doctors better assess clot risk in ITP and sort out which antibodies are involved.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
This study looks at whether chronic or persistent immune thrombocytopenia (ITP) affects thinking and memory. If you have had low platelet counts for 3 months or more and have been treated for ITP, you may help researchers understand how the condition can impact the brain.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
Hear when a new Immune Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.